Actively Recruiting
Safety and Efficacy of Stereotactic Body Radiation Therapy for Thoracic Malignant Tumors in Different Chest Regions
Led by Peking University Third Hospital · Updated on 2023-12-27
120
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the use of stereotactic body radiation therapy (SBRT) to treat malignant tumors in the chest area, including thoracic cancer. SBRT can deliver high doses of radiation precisely to the tumor while minimizing damage to nearby healthy organs. The study aims to understand the safety and effectiveness of SBRT in different chest regions, categorized as chest wall type, peripheral type, central type, and ultral-central type, because different chest organs tolerate radiation differently. Participants receive SBRT with doses ranging from 48 to 60 Gy over 4 to 10 treatment sessions, depending on the tumor location. The study groups are divided by tumor position relative to the chest wall, bronchial tree, and mediastinal structures. This approach helps explore how radiation dose and side effects vary by tumor site. During the study, researchers will monitor participants from the start of treatment up to 2 years afterward. They will assess local progression-free survival, radiation-related side effects, and overall survival. Participants will undergo evaluations to measure tumor control and treatment safety. The total study duration includes follow-up to track long-term outcomes and side effects.
CONDITIONS
Brief Title
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological diagnosis of malignant tumor
- Target lesion located in one of the defined chest region types with diameter 5 cm or less
- No extensive systemic metastasis or controlled metastasis after previous treatment
- Karnofsky Performance Status (KPS) above 70
- No serious or uncontrolled underlying diseases such as severe hypertension, diabetes, cardiovascular or cerebrovascular diseases, or organ dysfunction
- Patients expected to tolerate radiotherapy
You will not qualify if you...
- Poor basic lung function or symptoms preventing lying flat or cooperating with treatment
- Poor general condition with expected survival less than 3 months
- Psychiatric illness or poor compliance preventing completion of treatment
- Any other reason the researcher considers unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration as per individual treatment plan
Participants receive stereotactic body radiation therapy targeting thoracic malignant tumors using high-dose, low fractionated radiotherapy with modern precision technology.
1 to multiple visits depending on treatment schedule
Duration - Up to 2 years after treatment
Participants are monitored for local tumor control, toxicities, and overall survival for up to 2 years after treatment.
Regular follow-up visits for assessments during 2 years post-treatment
Trial Site Locations
Total: 1 location
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
Actively Recruiting
Research Team
Z
Zhe Ji, M.D.
J
Junjie Wang, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here